Ocular Therapeutix Posts $94.8M Q3 Loss; AXPAXLI NDA Still Set for Q4 2026
OCUL is trading near its 52-week low of $6 (1.0% above the low).
Summary
Ocular Therapeutix lost $94.8 million in Q3 2026 as R&D spending climbed, but holds $530.6 million in cash with runway into 2028 and still plans to file the AXPAXLI NDA for wet AMD in Q4 2026.
Key Events · Earnings and Guidance · OCUL
-
Q3 Net Loss Widens to $94.8M
Net loss was $(94.8) million, or $(0.42) per share, versus $(69.4) million, or $(0.38) per share, a year earlier. Revenue fell to $12.9 million from $14.5 million.
-
R&D Spending Jumps on Trial Enrollment
Research and development expenses rose to $74.8 million from $52.4 million, driven by accelerated HELIOS-3 and SOL-X enrollment plus added headcount and infrastructure.
-
Cash Runway Into 2028
Cash and cash equivalents stood at $530.6 million as of September 30, 2026, which the company says supports planned operating expenses, debt service and capex into 2028.
-
AXPAXLI NDA on Track for Q4 2026
Following a positive September 2026 Pre-NDA meeting, the wet AMD NDA remains planned for 4Q 2026 under the 505(b)(2) pathway, supported by SOL-1 Week 52 efficacy and SOL-1 plus interim SOL-R Week 52 safety data.
Analysis · OCUL · Life Sciences
The quarter was expensive: R&D jumped to $74.8 million from $52.4 million as HELIOS-3 and SOL-X enrollment accelerated, pushing the net loss to $94.8 million from $69.4 million a year ago. Revenue slipped to $12.9 million from $14.5 million. What matters more than the loss is the $530.6 million cash balance, which the company says funds operations into 2028 — past the planned Q4 2026 NDA submission and into a potential launch. The SOL-R primary endpoint moved to Week 40 from Week 56, with topline now guided to 1Q 2028, so the confirmatory trial reads out well after the NDA is filed. The stock sits near its 52-week low of $6.00, so the market is already pricing skepticism; the NDA submission and the interim SOL-R Week 52 safety analysis in Q4 2026 are the next hard checkpoints.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OCUL was trading at $6.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $6.00 to $16.44. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.